PortfoliosLab logoPortfoliosLab logo
ALT vs. METCB
Performance
Return for Risk
Dividends
Drawdowns
Volatility
Financials

Performance

ALT vs. METCB - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Altimmune, Inc. (ALT) and Ramaco Resources Inc. (METCB). The values are adjusted to include any dividend payments, if applicable.

Loading graphics...

ALT vs. METCB - Yearly Performance Comparison


2026 (YTD)202520242023
ALT
Altimmune, Inc.
-14.68%-49.93%-35.91%170.43%
METCB
Ramaco Resources Inc.
-12.15%25.90%-17.35%24.77%

Fundamentals

EPS

ALT:

-$0.97

METCB:

-$1.55

PS Ratio

ALT:

6.80K

METCB:

0.63

Total Revenue (TTM)

ALT:

$41.00K

METCB:

$536.62M

Gross Profit (TTM)

ALT:

-$14.95M

METCB:

$23.52M

EBITDA (TTM)

ALT:

-$89.46M

METCB:

$13.61M

Returns By Period

In the year-to-date period, ALT achieves a -14.68% return, which is significantly lower than METCB's -12.15% return.


ALT

1D
6.94%
1M
-28.54%
YTD
-14.68%
6M
-18.30%
1Y
-38.40%
3Y*
-9.96%
5Y*
-26.13%
10Y*
-40.86%

METCB

1D
0.89%
1M
-12.37%
YTD
-12.15%
6M
-38.74%
1Y
50.31%
3Y*
5Y*
10Y*
*Multi-year figures are annualized to reflect compound growth (CAGR)

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Altimmune, Inc.

Ramaco Resources Inc.

Return for Risk

ALT vs. METCB — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

ALT
ALT Risk / Return Rank: 2626
Overall Rank
ALT Sharpe Ratio Rank: 2323
Sharpe Ratio Rank
ALT Sortino Ratio Rank: 3131
Sortino Ratio Rank
ALT Omega Ratio Rank: 3232
Omega Ratio Rank
ALT Calmar Ratio Rank: 1818
Calmar Ratio Rank
ALT Martin Ratio Rank: 2424
Martin Ratio Rank

METCB
METCB Risk / Return Rank: 6363
Overall Rank
METCB Sharpe Ratio Rank: 6565
Sharpe Ratio Rank
METCB Sortino Ratio Rank: 6767
Sortino Ratio Rank
METCB Omega Ratio Rank: 6161
Omega Ratio Rank
METCB Calmar Ratio Rank: 6464
Calmar Ratio Rank
METCB Martin Ratio Rank: 6060
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

ALT vs. METCB - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Altimmune, Inc. (ALT) and Ramaco Resources Inc. (METCB). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


ALTMETCBDifference

Sharpe ratio

Return per unit of total volatility

-0.41

0.62

-1.04

Sortino ratio

Return per unit of downside risk

0.05

1.44

-1.38

Omega ratio

Gain probability vs. loss probability

1.01

1.16

-0.15

Calmar ratio

Return relative to maximum drawdown

-0.67

0.97

-1.64

Martin ratio

Return relative to average drawdown

-1.02

1.86

-2.89

ALT vs. METCB - Sharpe Ratio Comparison

The current ALT Sharpe Ratio is -0.41, which is lower than the METCB Sharpe Ratio of 0.62. The chart below compares the historical Sharpe Ratios of ALT and METCB, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Loading graphics...

Sharpe Ratios by Period


ALTMETCBDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

-0.41

0.62

-1.04

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

-0.28

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

-0.29

Sharpe Ratio (All Time)

Calculated using the full available price history

-0.24

0.08

-0.32

Correlation

The correlation between ALT and METCB is 0.13, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


Dividends

ALT vs. METCB - Dividend Comparison

ALT has not paid dividends to shareholders, while METCB's dividend yield for the trailing twelve months is around 1.74%.


TTM202520242023
ALT
Altimmune, Inc.
0.00%0.00%0.00%0.00%
METCB
Ramaco Resources Inc.
1.74%3.18%9.36%3.11%

Drawdowns

ALT vs. METCB - Drawdown Comparison

The maximum ALT drawdown since its inception was -99.94%, which is greater than METCB's maximum drawdown of -56.22%. Use the drawdown chart below to compare losses from any high point for ALT and METCB.


Loading graphics...

Drawdown Indicators


ALTMETCBDifference

Max Drawdown

Largest peak-to-trough decline

-99.94%

-56.22%

-43.72%

Max Drawdown (1Y)

Largest decline over 1 year

-62.65%

-55.65%

-7.00%

Max Drawdown (5Y)

Largest decline over 5 years

-90.45%

Max Drawdown (10Y)

Largest decline over 10 years

-99.85%

Current Drawdown

Current decline from peak

-99.89%

-52.37%

-47.52%

Average Drawdown

Average peak-to-trough decline

-80.66%

-27.90%

-52.76%

Ulcer Index

Depth and duration of drawdowns from previous peaks

41.12%

28.84%

+12.28%

Volatility

ALT vs. METCB - Volatility Comparison

Altimmune, Inc. (ALT) has a higher volatility of 26.59% compared to Ramaco Resources Inc. (METCB) at 19.76%. This indicates that ALT's price experiences larger fluctuations and is considered to be riskier than METCB based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading graphics...

Volatility by Period


ALTMETCBDifference

Volatility (1M)

Calculated over the trailing 1-month period

26.59%

19.76%

+6.83%

Volatility (6M)

Calculated over the trailing 6-month period

58.39%

57.98%

+0.41%

Volatility (1Y)

Calculated over the trailing 1-year period

93.96%

80.94%

+13.02%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

94.38%

65.17%

+29.21%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

142.47%

65.17%

+77.30%

Financials

ALT vs. METCB - Financials Comparison

This section allows you to compare key financial metrics between Altimmune, Inc. and Ramaco Resources Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.0050.00M100.00M150.00M200.00MAprilJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober2025AprilJulyOctober
26.00K
128.01M
(ALT) Total Revenue
(METCB) Total Revenue
Values in USD except per share items